Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
Inmune Bio, Inc. shows accelerating business momentum based on AlphaOS pipeline evidence.
3 signals not yet derived from pipeline evidence
Pipeline evidence · 22d ago
INMB's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on INMB.
Free accounts see more of this; Premium sees all of it.
Reported figures for Inmune Bio, Inc. — research only, not investment advice.
Updated
What happened recently for Inmune Bio, Inc. (INMB) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
INMB's AI investment thesis
Upgrade to Premium for INMB's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$2.00
Market cap
$55.51M
Profitable
No
Revenue $50,000.00
Net income
$-45.93M
FY Dec 31, 2025
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Healthcare · Biological Products, (No Diagnostic Substances)
Investment Snapshot above is the primary AlphaOS analysis for Inmune Bio, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Inmune Bio, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.